Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer

Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-02, Vol.104, p.45-51
Hauptverfasser:	Paz-Ares, Luis G, Zimmermann, Annamaria, Ciuleanu, Tudor, Bunn, Paul A, Antonio, Belen San, Denne, Jonathan, Iturria, Nancy, John, William, Scagliotti, Giorgio V
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced non-small cell lung cancer Age Factors Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Cisplatin - therapeutic use Clinical Trials, Phase III as Topic Disease-Free Survival Elderly Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - epidemiology Lung Neoplasms - mortality Meta-analysis Overall survival Pemetrexed Pemetrexed - therapeutic use Platinum - therapeutic use Pulmonary/Respiratory Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We examined impact of age on OS with pemetrexed for treatment of non-squamous NSCLC. • This meta-analysis included 2671 patients, 386 ≥ 70 years, from 4 pemetrexed studies. • OS benefit from pemetrexed was not found to be different in younger and older patients across different therapeutic settings. • Overall, our results support the effectiveness of pemetrexed in fit elderly patients. • Our findings support evidence indicating that age alone should not dictate lung cancer treatment.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.12.007